Although PARP1 inhibitors are primarily used in the clinic to treat cancers with an impaired homologous recombination signaling pathway (especially BRCA1 mutation), they have recently been used as part of an adjunctive therapy in other solid cancers. Here, PARP1 is linked to cancer.